Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
Expanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious Diseases
GlobeNewswire, Inc.
COPENHAGEN, Denmark, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SNIPR today announced the publication of a peer-reviewed expanded access case report in Clinical Infectious Diseases https://doi.org/10.1093/cid/ciag446 describing the use of SNIPR001 in a...
Novonesis launches Optiva® Triticum to help pasta manufacturers navigate wheat volatility without compromising quality
GlobeNewswire, Inc.
COPENHAGEN, Denmark, August 12, 2026 – Novonesis today announced the launch of Optiva® Triticum, a new biosolution that helps pasta manufacturers increase flexibility in wheat sourcing while maintaining the texture, firmness and eating experience...
Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)
GlobeNewswire, Inc.
Company announcement No. 37 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 32, 2026) Copenhagen, Denmark, August 10, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...
Rinn Pharma & Biopharma Expands European Research Collaboration Through NordicPharmaTrain Partnership
EIN Presswire
Rinn Pharma & Biopharma expanding collaborative research and training across the Nordic and European innovation landscape.
Zealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial results
GlobeNewswire, Inc.
Press Release – No. 14 / 2026 Zealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial results Copenhagen, Denmark, August 6, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a...
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
GlobeNewswire, Inc.
Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA® in type 1 diabetes nearing completion Phase 1 clinical development of LX9851 ongoing by Novo Nordisk Conference call and...
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
GlobeNewswire, Inc.
Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved Targeted Therapy to Treat GBS Worldwide,...
Anteris Technologies Announces Results for the Second Quarter of 2026
GlobeNewswire, Inc.
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing...
H1 Partners with Novo Nordisk to Scale AI-Driven Clinical Development
GlobeNewswire, Inc.
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- H1 today announced a new partnership with Novo Nordisk to improve clinical development in the age of AI. The partnership aims to develop proprietary AI-ready data and AI-powered clinical development...
Randomized U.S. Trial Finds Autonomous System Improves Precision of Hospital Oxygen Therapy
GlobeNewswire, Inc.
Copenhagen, Denmark, Aug. 03, 2026 (GLOBE NEWSWIRE) -- — O2matic ApS today announced results from a randomized, multicenter U.S. clinical trial showing that hospitalized patients receiving autonomous oxygen titration with the O2matic PRO 100 spent...
NRG Therapeutics Announces the Appointment of Claus Sundgreen M.D. as Chief Medical Officer
GlobeNewswire, Inc.
STEVENAGE, United Kingdom, Aug. 03, 2026 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company developing novel disease-modifying therapeutics that rectify mitochondrial dysfunction in neurodegenerative diseases,...
Zealand Pharma - Transactions related to share buy-back program (week 31, 2026)
GlobeNewswire, Inc.
Company announcement No. 36 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 31, 2026) Copenhagen, Denmark, August 3, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire, Inc.
Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France New clinical data on HMB-002 demonstrated 2.4-fold...
BioAgeDiagnostics Strengthens Global Medical Advisory Board with Dr. Stuart M. Diamond
EIN Presswire
Board-certified longevity physician and surgeon joins BioAgeDiagnostics to accelerate the global adoption of precision longevity diagnostics.
Zealand Pharma - Transactions related to share buy-back program (week 30, 2026)
GlobeNewswire, Inc.
Company announcement No. 35 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 30, 2026) Copenhagen, Denmark, July 27, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...
NMD Pharma Announces Publication Identifying Neuromuscular Junction Transmission Failure as a Novel Contributor to Age-Related Muscle Weakness
GlobeNewswire, Inc.
New publication identifies neuromuscular junction transmission failure as a novel mechanism contributing to sarcopenia, with preclinical studies showing that ClC-1 inhibition improves neuromuscular transmission and muscle function NMD Pharma is...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
GlobeNewswire, Inc.
Company announcement – No. 34 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, July 20, 2026 – Zealand Pharma A/S...
Zealand Pharma: Transactions related to share buy-back program (week 29, 2026)
GlobeNewswire, Inc.
Company announcement No. 33 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 29, 2026) Copenhagen, Denmark, July 20, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...
Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01
GlobeNewswire, Inc.
STAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an...
Alpine Psychiatry Offers Comprehensive Mental Health Services Across Pennsylvania
EIN Presswire
Clinician-owned practice provides in-person and virtual psychiatric care and therapy to patients across Pennsylvania, New Jersey, and New York. KING OF PRUSSIA, PA, UNITED STATES, July 16, 2026 /EINPresswire.com/ -- Alpine Psychiatry, a...
Sign up for:
Healthcare Times Denmark
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.